Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.45 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5626913 | 1.00 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1KDM4EMEN1 | |
| SCHEMBL5627506 | 0.93 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1MBTD1KDM4EMEN1 | |
| SCHEMBL5628972 | 0.88 | AVPR2 (0.48) | MEN1ALDH1A1KMT2AAVPR1ANAMPT | |
| SCHEMBL5629638 | 0.86 | AVPR2 (0.46) | MEN1ALDH1A1KMT2AAVPR1AAVPR2 | |
| SCHEMBL5626957 | 0.85 | AVPR1A (0.42) | ALDH1A1AVPR1AAVPR2HTR2B | |
| SCHEMBL5784232 | 0.85 | AVPR2 (0.54) | L3MBTL3L3MBTL1MBTD1KDM4EMEN1 | |
| SCHEMBL5627644 | 0.84 | NAMPT (0.44) | ALDH1A1AVPR1ANAMPTAVPR2HTR2B | |
| SCHEMBL5626780 | 0.84 | TSHR (0.45) | AVPR1AAVPR2HTR2B | |
| SCHEMBL5626277 | 0.84 | AVPR1A (0.48) | ALDH1A1AVPR1AAVPR2HTR2B | |
| SCHEMBL5783445 | 0.84 | AVPR2 (0.54) | L3MBTL3L3MBTL1MBTD1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-02-06 | — | — | US | claimed |
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1377582-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| WO-2002085907-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, CRHR2 | L3MBTL3 3571/4885L3MBTL1 3600/4885MBTD1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.